Friday, December 01, 2023

Pursuing justice’: Texas sues Pfizer for overstating COVID-19 vaccine effectiveness

Texas Attorney-General Ken Paxton has accused Pfizer of misrepresenting the effectiveness of the company’s COVID-19 vaccine in a lawsuit filed in state court.

The pharmaceutical giant used misleading statistics to promote its vaccine and sought to “intimidate and silence” those who questioned the product’s efficacy, the lawsuit, filed on Thursday Austin-time, alleges.

Paxton is seeking more than $US10 million ($15 million) in civil fines and a court order barring Pfizer from speaking publicly about the efficacy of its vaccine.

“We are pursuing justice for the people of Texas, many of whom were coerced by tyrannical vaccine mandates to take a defective product sold by lies,” Paxton said in a statement.

The lawsuit follows a probe launched by Paxton’s office in May into three major drug companies related to claims they made about the effectiveness of their vaccines. Paxton has been a vocal opponent of COVID-19 safety mandates since the onset of the pandemic.

In the complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95 per cent effective because it offered a “relative risk reduction” for people to who took it.

Paxton said the claim was based on only two months of clinical trial data, and claimed the pandemic got worse even after people started taking Pfizer’s vaccine.

“Pfizer intentionally misrepresented the efficacy of its COVID-19 vaccine and censored persons who threatened to disseminate the truth in order to facilitate fast adoption of the product and expand its commercial opportunity,” the complaint said.

Paxton’s statement included the claim: “COVID-19 cases increased after widespread vaccine administration, and some areas saw a greater percentage of deaths from COVID-19 among the vaccinated population than the unvaccinated.”

“When the failure of its product became apparent, Pfizer then pivoted to silencing truth-teller


Study suggests pandemic lockdowns accelerated ‘significant’ memory and cognitive decline in seniors

Follow America's fastest-growing news aggregator, Spreely News, and stay informed. You can find all of our articles plus information from your favorite Conservative voices.
A new study conducted by the University of Exeter Medical School, led by Dr. Anne Corbett, has revealed that the lockdowns and societal restrictions imposed during the pandemic had a detrimental impact not only on the mental health of children and teens, but also on elderly individuals.

Using data collected from 3,142 people aged 50 years or over who were taking part in a long-term dementia study in Britain, it was observed that there was a significant worsening of executive function and working memory among the cohort (average age 67.5) in both the first and second year of lockdowns.

Despite restrictions being eased after this period, it appears that much damage had already been done.

The study revealed that reduced exercise and increased drinking were significantly associated with cognitive decline among the entire cohort. Notably, depression was a prominent factor of cognitive decline among those who contracted COVID-19.

Additionally, it was found that loneliness had especially detrimental effects on those with mild cognitive impairment.

“People aged 50 years and older in the UK had accelerated decline in executive function and working memory during the first year of the COVID-19 pandemic, during which the UK was subjected to three societal lockdowns for a total period of 6 months,” said the study, published in the Lancet journal Healthy Longevity.

The British Government, funded by the National Institute for Health and Care Research, implemented restrictions on the number of times citizens could exercise outside during the pandemic, as well as closing gyms, golf courses, sports courts, swimming pools and indoor sports facilities.

“The scale of change is also of note, with all groups—the whole cohort and the individual subgroups—showing more than a 50% greater decline in working memory and executive function and many effect sizes reaching a clinically significant threshold of greater than 0·3,” said the researchers.

Governments across the West have implemented lockdown measures on and off throughout the pandemic, despite early indications that serious cognitive decline would be a consequence, especially for elderly individuals.

For example, Italian scientists noted in an October 2020 paper in Frontiers in Psychiatry that social disconnection – which is practically guaranteed by the closure of voluntary associations, churches, parishes, gyms and other meeting places for seniors – is a risk factor for dementia and likely to increase the risk of depression and anxiety amongst elderly people.

The researchers further highlighted that these factors mirror population-wide changes in health and lifestyle seen during and after lockdowns, prompting a pertinent question regarding the impact of the pandemic on cognitive health and risk across populations.

“Lockdown could affect disproportionately the mental health of old people, whom relatives contracted COVID-19, people who live alone and whose only social contacts take place outside home, and people who do not have close relatives or friends and rely on the support of voluntary services or social assistance,” said the paper.


Half-Dose of COVID-19 Booster Just as Effective as a Full Dose: Study

Reducing the dose of a Pfizer COVID-19 booster vaccine can elicit a comparable immune response in adults compared to a full dose with fewer side effects, new research has found.

Led by the Murdoch Institute and the National Centre for Communicable Diseases in Mongolia, the study involved 601 participants over 18 years old from Mongolia, and is the first to assess and compare widely used COVID-19 vaccines in low- and middle-income countries.

The study focused on adults who had previously received AstraZeneca or Sinopharm COVID-19 shots, finding that a half dose of the Pfizer booster produced a non-inferior immune response.

Murdoch Institute’s Professor Kim Mulholland said reduced doses would make booster programs more cost-effective.

“Fractional dosing may improve COVID-19 booster acceptability and uptake and reduce the per-dose cost of COVID-19 booster programs,” he said.

“Policymakers and immunisation advisory committees can draw upon this data to make flexible boosting schedules decisions.”

However, the study noted that half-dose boosting may be less effective in adults primed with the Russian COVID-19 vaccine, Sputnik V.

Fewer Side Effects for Half Doses

Participants receiving half doses reported fewer side effects compared to those receiving full doses, highlighting the potential benefits of this approach.

Among half-dose boosted participants, 60 percent reported local reactions including pain and tenderness, and 25 percent reported systemic reactions including fevers, vomiting, diarrhoea, and headaches.

On the other hand, 72 percent of full-dose boosted participants reported local reactions, and 32 percent reported system reactions.

The study will continue to follow up on participants at six and 12-month intervals to explore their immune response, such as waning rates and breakthrough infections.

FDA Vaccine Adviser: Most Don't Need Yet Another COVID-19 Booster

This comes amid recommendations from the Food and Drug Administration's (FDA) vaccine adviser Dr. Paul Offit that most people did not need another COVID-19 booster.
In an article in a medical journal, he said that asking young, healthy people to get boosted with a variant-specific booster was pointless.

“I believe we should stop trying to prevent all symptomatic infections in healthy, young people by boosting them with vaccines containing mRNA from strains that might disappear a few months later,” Dr. Offit wrote in the paper.

Medical researcher and immunology specialist Kevin Bass echoed his sentiment saying people were likely to take a hard pass on the new COVID-19 booster shot unless it was mandated.

“Public opinion has swung so hard against the vaccines that I can’t imagine a scenario where a significant amount of people are going to sign up for another shot,” he told The Epoch Times in a recent interview. “If people have the choice, they are going to say no.”

Global Trial Investigating Reduced COVID-19 Boosters
The new research was published in the Lancet, and is part of an international clinical trial funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

This trial, involving 3,300 healthy adults across Australia, Indonesia, and Mongolia, investigates the impact of administering a reduced dose of COVID-19 booster shots.

The efficacy, side effects, and acceptability of fractional doses explored will inform flexible booster strategies and address global vaccine supply challenges.

CEPI receives funding from the Australian government.




No comments: